BioNxt Solutions Inc
Commented by André Will-Laudien on November 2nd, 2026 | 05:43 CET
The Biotech breakout: Bayer and Eli Lilly flex their muscles - are Novo Nordisk, Evotec and BioNxt the next winners?
That was a week of selling on the NASDAQ! The technology index lost a full 5% in its renewed attempt to exceed the 30,000-point mark. Chip stocks, which had previously performed excellently, came under considerable pressure, followed by subdued figures from Alphabet, Microsoft and, most recently, Intel. The result was hefty double-digit losses; this sector has not seen this much uncertainty in a long time. Things are very different in the biotech sector. At 7,319 points, the underlying NASDAQ Biotech Index only narrowly missed its all-time high of 7,458 points. Leading players such as Bayer and Eli Lilly brought a breath of fresh air to the sector, which could now significantly outperform other industries towards the end of the year. We take a closer look at some of the protagonists.
Read
Commented by Armin Schulz on October 27th, 2026 | 05:21 CET
Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines
No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.
Read
Commented by Matthias Schomber on October 23rd, 2026 | 05:42 CEST
Puma Boardroom Shake-Up, Margin Pressure at BYD and Clinical Milestones at BioNxt Solutions
Sportswear manufacturer Puma is pressing ahead with its strategic realignment following a change of ownership and the arrival of Anta Sports as a shareholder. Chinese electric vehicle group BYD is grappling with regulatory hurdles and declining export margins. In the advanced drug delivery segment, BioNxt Solutions is attracting investors' attention with clinical progress and an interesting chart pattern. This article analyses the opportunities and risks of these three stocks. A close look at their fundamentals and technicals shows where key entry and turning points could lie for investors in the coming days and weeks.
Read
Commented by Lars Winter on October 13th, 2026 | 05:22 CEST
BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge
On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.
Read
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read
Commented by André Will-Laudien on September 29th, 2026 | 07:10 CEST
Takeovers and Blockbusters on the Horizon! Novo Nordisk, BioNxt and Bayer Keep Taking Center Stage
The storm continues! The biotech sector is facing a massive wave of acquisitions and the approval of new blockbuster drugs. Currently in the spotlight are, above all, the weight-loss sector, innovative drug-delivery platforms, and groundbreaking gene therapies. Major pharmaceutical companies are sitting on bulging cash reserves and are desperately seeking innovative pipelines to offset impending patent expirations. In addition, approval decisions for novel obesity treatments and cancer therapies are driving up valuations across the entire industry. Smaller research firms are making a name for themselves with revolutionary active-ingredient delivery technologies, making them coveted acquisition targets for industry giants. Artificial intelligence in clinical development is also driving major efficiency gains and attracting massive amounts of venture capital. Current market momentum shows industry consolidation is in full swing, and strategic partnerships are setting the pace. Those who stay ahead of the curve in this environment will secure strong revenues for decades to come. For investors and market observers, this realignment offers an exciting starting point with enormous growth opportunities. We dive a little deeper!
Read
Commented by Armin Schulz on September 21st, 2026 | 07:30 CEST
Novo Nordisk, BioNxt Solutions, Evotec: When Injections Become Pills, The Cash Starts Rolling In
The daily injection has had its day. For a long time, taking biologics in pill form was considered a pipe dream, but as of this year, it is becoming a billion-dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to USD 1.4 billion to make injections available orally. In February, the Danish company secured a partnership with Vivtex worth up to USD 2.1 billion. Whoever can deliver peptides through the stomach could see the industry come knocking. We are taking a closer look at Novo Nordisk, BioNxt Solutions and Evotec, which cover the entire spectrum of this trend—from acquisitions to technology to development.
Read
Commented by Nico Popp on September 16th, 2026 | 06:55 CEST
The End of Weight-Loss Shots? Innovations at Merck and Novo Nordisk—BioNxt Solutions Poised for a Hot Fall?
The battle against excess weight is no longer merely a lifestyle issue. Medical professionals now view extreme obesity as a chronic disease that weakens the body and can lead to serious cardiovascular conditions, as cardiological studies have shown. By contrast, sustained weight loss can help pave the way to a longer, healthier life. This insight, combined with pharmaceutical innovation, has sparked an unprecedented race to develop weight-loss drugs. Companies are searching for the ideal way to boost metabolism while making medication as easy and convenient to take as possible.
Read
Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST
Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash
After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.
Read
Commented by Armin Schulz on September 4th, 2026 | 07:35 CEST
From the Pill to the Dissolving Film and the Monthly Injection for Obesity: Novo Nordisk, BioNxt Solutions and Pfizer
Obesity treatment is undergoing a transformation. Following the initial success of GLP-1 medications, the next round is now underway. It is no longer just about efficacy, but also about the method of administration. Novo Nordisk was the first to launch the oral pill on the European market and is already testing lower maintenance doses. BioNxt Solutions is countering with oral dissolvable thin films (ODFs) that require neither a needle nor water. Pfizer, meanwhile, is focusing on a monthly ultra-long-acting GLP-1 derived through its acquisition of Metsera. Today we take a closer look at the strategies of Novo Nordisk, BioNxt Solutions and Pfizer.
Read